Zobrazeno 1 - 10
of 2 208
pro vyhledávání: '"Pharmacometrics"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipraglifloz
Externí odkaz:
https://doaj.org/article/c8f7851be87649e49f1166c1f49d57a8
Autor:
Josiah Ryman, Jeffrey R. Sachs, Natalie Banniettis, Thomas Weiss, Maurice Ahsman, Ka Lai Yee, Jessica Weaver
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 467-473 (2024)
ABSTRACTBackground Next generation, higher valency pneumococcal conjugate vaccines (PCVs) are assessed and licensed by comparing the immune response across serotypes shared with the PCVs that are standard of care for prevention of pneumococcal diseas
Externí odkaz:
https://doaj.org/article/da5b7b5fa7ff48d19e008136d16f17f4
Publikováno v:
Anaesthesiology Intensive Therapy, Vol 56, Iss 2, Pp 129-140 (2024)
Externí odkaz:
https://doaj.org/article/8bbb1ddd7429467a924cd4af42b63bfd
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/01306313d5f5433e8d330423c6a1a7ca
Autor:
Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Steve Dang, Dale Miles, James Lu
Publikováno v:
Frontiers in Artificial Intelligence, Vol 7 (2024)
In oncology drug development, tumor dynamics modeling is widely applied to predict patients' overall survival (OS) via parametric models. However, the current modeling paradigm, which assumes a disease-specific link between tumor dynamics and surviva
Externí odkaz:
https://doaj.org/article/d7fbc5a18a1244648d453f8c2e75b4e2
Autor:
Viravarn Luvira, William H. K. Schilling, Podjanee Jittamala, James A. Watson, Simon Boyd, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J. Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J. Callery, Shivani Singh, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S. Aguiar, Franciele M. Santos, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mallika Imwong, Walter R. J. Taylor, Vasin Chotivanich, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P. J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White, the PLATCOV Collaborative Group
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence
Externí odkaz:
https://doaj.org/article/38be8586c0b14f9a9e31989e8009d6df
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 81-95 (2024)
Khalid Altigani Ahmed,1 Alnada Ibrahim,2 Daniel Gonzalez,3 Abubakr O Nur4 1Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Saudi Arabia; 2Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdu
Externí odkaz:
https://doaj.org/article/a3cc72ba630c4d6a92bfec2aa3f2a5b7
Autor:
Klervi Golhen, Michael Buettcher, Jörg Huwyler, John van den Anker, Verena Gotta, Kim Dao, Laura E. Rothuizen, Kevin Kobylinski, Marc Pfister
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1186 (2024)
The antiparasitic drug ivermectin is approved for persons > 15 kg in the US and EU. A pharmacometric (PMX) population model with clinical PK data was developed (i) to characterize the effect of the patient-friendly ivermectin formulation CHILD-IVITAB
Externí odkaz:
https://doaj.org/article/12e1f1321610492b84aa70d719982c48
Autor:
L.A. Felix, L.W.F. Gonzaga, B.C.F. Soares, G. Suárez, H.M. Brandão, P.Y. Faccioli-Martins, M. Ferrante
Publikováno v:
Arquivo Brasileiro de Medicina Veterinária e Zootecnia, Vol 75, Iss 6, Pp 1087-1096 (2023)
ABSTRACT This study aims to determine therapeutic protocols of intramuscular sodium cloxacillin (IM) in goats with potential antibacterial effects against Staphylococcus spp. We constructed a pharmacokinetic (PK) model of IM, followed by a pharmacoki
Externí odkaz:
https://doaj.org/article/520442b48392477aa4a0b43b5d53652e
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 13, Iss 6, Pp 660-672 (2023)
Fexofenadine is useful in various allergic disease treatment. However, the pharmacokinetic variability information and quantitative factor identification of fexofenadine are very lacking. This study aimed to verify the validity of previously proposed
Externí odkaz:
https://doaj.org/article/7ed1eb62e0c44124866c3dd304df18c3